Display options
Cite
Philipp M, Lesch OM, Schmauss M, et al. Vergleichbare Wirksamkeit von Flupentixol und Risperidon auf schizophrene Negativsymptomatik. [Comparative Efficacy of Flupentixol and Risperidone on Schizophrenic Negative Symptoms]. Psychiatr Prax. 2003;30:94-96doi: 10.1055/s-2003-39746.
Philipp, M., Lesch, O. M., Schmauss, M., Dose, M., & Glaser, T. (2003). Vergleichbare Wirksamkeit von Flupentixol und Risperidon auf schizophrene Negativsymptomatik. [Comparative Efficacy of Flupentixol and Risperidone on Schizophrenic Negative Symptoms]. Psychiatrische Praxis, 3094-96. https://doi.org/10.1055/s-2003-39746
Philipp, Michael, et al. "Vergleichbare Wirksamkeit von Flupentixol und Risperidon auf schizophrene Negativsymptomatik." [Comparative Efficacy of Flupentixol and Risperidone on Schizophrenic Negative Symptoms]. Psychiatrische Praxis vol. 30 (2003): 94-96. doi: https://doi.org/10.1055/s-2003-39746
Philipp M, Lesch OM, Schmauss M, Dose M, Glaser T. Vergleichbare Wirksamkeit von Flupentixol und Risperidon auf schizophrene Negativsymptomatik. [Comparative Efficacy of Flupentixol and Risperidone on Schizophrenic Negative Symptoms]. Psychiatr Prax. 2003 May;30:94-96. doi: 10.1055/s-2003-39746. German. PMID: 13130348.
Copy Download .nbib Format: NLM
Share it on

Psychiatr Prax. 2003 May;30:94-96. doi: 10.1055/s-2003-39746.

[Comparative Efficacy of Flupentixol and Risperidone on Schizophrenic Negative Symptoms].

Psychiatrische Praxis

[Article in German]
Michael Philipp, Otto M. Lesch, Max Schmauss, Matthias Dose, Thomas Glaser

Affiliations

  1. Bezirkskrankenhaus Landshut.

PMID: 13130348 DOI: 10.1055/s-2003-39746

Abstract

The efficacy of flupentixol and risperidone were compared in a randomized double-blind study in 153 chronic schizophrenic patients. Flupentixol showed to be not inferior to risperidone concerning schizophrenic negative symptoms at week 8, 16 and 24. Positive symptoms and general psychopathology improved comparably, too. There was a trend in favor of flupentixol concerning the improvement of depressive symptoms and a trend in favor of risperidone concerning the improvement of preexisting parkinsonian symptoms. The study data justify to regard flupentixol as a "partial atypical" antipsychotic.

Publication Types